Farther Finance Advisors’s TherapeuticsMD TXMD Stock Holding History

Farther Finance Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$61	Sell	30 -9	-23%	-$19	﹤0.01%	6014
2026 Q2	$86	Buy	39 +8	+26%	+$17	﹤0.01%	5805
2026 Q1	$62	Buy	31 +1	+3%	+$2	﹤0.01%	5558
2025 Q4	$49	Hold	30	–	–	﹤0.01%	5355
2025 Q3	$32	Hold	30	–	–	﹤0.01%	4890
2025 Q2	$35	Hold	30	–	–	﹤0.01%	4396
2025 Q1	$29	Buy	+30	New	+$30	﹤0.01%	4170

Other funds holding TXMD

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Farther Finance Advisors's TXMD Position: Q3 2026 in Review

Farther Finance Advisors reduced its TherapeuticsMD (TXMD) stake by 23% in Q3 2026, selling an estimated $19 and leaving 30 shares worth $61. The position accounts for ﹤0.01% of the portfolio, ranked #6014.

Farther Finance Advisors first reported a position in TXMD in Q1 2025 and has held it in 7 quarters since. The position peaked at $86 in Q2 2026. 2 funds tracked by Wall St. Rank hold TXMD as of Q3 2026.

Farther Finance Advisors held 30 shares of TherapeuticsMD worth $61 as of Q3 2026.
Farther Finance Advisors sold 9 TherapeuticsMD shares in Q3 2026, an estimated $19.
TherapeuticsMD made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #6014 holding.
Farther Finance Advisors first reported a position in TherapeuticsMD in Q1 2025 and has held it in 7 quarters since.
Farther Finance Advisors's TherapeuticsMD position peaked at $86 in Q2 2026.
2 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.